PepGen shares jump 90% on an early muscular dystrophy result
Shares in biotech PepGen rose more than 90% on Tuesday. Its drug for myotonic dystrophy type 1 fixed on average 46.5% of the faulty RNA errors in six patients. They had four monthly doses. Side effects were mild to moderate. The trial is small, and US regulators still partly block dosing there.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.